• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice

tetano

Editor, Senior Moderator
Antiviral Res. 2011 Dec 8. [Epub ahead of print]
Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice.
Tarasov SA, Zarubaev VV, Gorbunov EA, Sergeeva SA, Epstein OI.
Source

OOO "NPF "MATERIA MEDICA HOLDING", 3rd Samotyochnyi per. 9, Moscow 127473, Russia.
Abstract
BACKGROUND:

The influenza A virus is a highly infective agent that causes acute pulmonary diseases. In serious cases, it causes pneumonia which is particularly fatal in patients with cardiopulmonary diseases, obesity, young children and elderly people. The present study shows a protective effect of ultra-low doses of purified antibodies to gamma-interferon (Anaferon for children?, AC?) against lethal influenza virus infection caused by pandemic influenza virus A(H1N1) in mice.
METHODS:

Balb/c mice were infected with mouse-adapted pandemic influenza virus A/California/07/09 (H1N1)v. Mortality, weight loss, infectious titer of the virus in lungs and lung morphology were monitored in the groups of AC?-, oseltamivir- and placebo-treated animals.
RESULTS:

The protective action of AC? was demonstrated by prolongation of life of the infected animals, reduction of infectious titer of the virus in the lung tissue, normalization of weight dynamics in the course of disease, decrease in mortality of treated animals compared to a placebo control and normalization of lung tissue structure. The protective activity of AC? was similar to that of the reference compound oseltamivir. Combination of AC? with oseltamivir resulted in a higher protective effect comparing to oseltamivir alone.
CONCLUSION:

Based on the results obtained, AC? should be considered as an important part of anti-influenza prophylaxis and therapy, in particular in severe cases of the disease.

Copyright ? 2011. Published by Elsevier B.V.

PMID:
22178245
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22178245
 
Back
Top Bottom